Home » Newsletters » BioWorld Science

BioWorld Science

June 2, 2006

View Archived Issues

Recent studies with FXR agonist INT-747 highlight FXR's role in IBD

Effects of ABN-912 evaluated in chronic obstructive pulmonary disease patients

WK-X-34: targeting Pgp and BCRP ABC transporters to improve tumor responses to chemotherapy

FDA accepts for review Adolor's response to Entereg approvable letter

Phase III trial studies enzastaurin in NHL

Topline data from phase II study of MLN-1202 in patients at risk for atherosclerosis

Pharmexa seeks approval to begin phase II study of GV-1001 in liver cancer

Refusal to file letter for RSD-1235 (i.v.) NDA

Corautus Genetics files response to FDA clinical hold on GENASIS trial

Icagen studies ICA-17043 in pediatric sickle cell disease patients

European orphan medicinal product status for Increlex for primary IGFD

Biogen Idec to acquire Fumapharm

Phase III study of Intercell's Japanese encephalitis vaccine meets primary endpoint

International study to test new drug combination to cut cardiovascular disease

Japanese approval sought for garenoxacin

MC-4232 improves blood pressure and metabolic outcome in patients with type 2 diabetes

European approval for Evoltra in relapsed or refractory pediatric ALL

Novel microtubule targeting agents presented by Nereus Pharmaceuticals

Abbott discovers novel multitargeted receptor tyrosine kinase inhibitor

BioNetWorks presents data on novel potential therapeutic target in rheumatoid arthritis

Fast track designation for IL-1 Trap program

Vesicare to be launched in Japan

FDA approves Orapred ODT

Orphan drug status for ISIS-301012 in homozygous familial hypercholesterolemia

Japanese NHI price listing for Nicotinell TTS

New preclinical and clinical data on NVA-237 for COPD reported

Novel histone deacetylase inhibitor shows synergy with azole antifungals

Antimitotic sulfonamide analogues show antiproliferative efficacy in vitro

New HIV reverse transcriptase inhibitors reported in recent Tibotec patent

Recent patents impart new therapeutic agents for cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Pharma industry faces long haul to get return on investment from AI
BioWorld Science
Artificial intelligence tools are springing up at multiple points along drug discovery and development, but despite the hype, as yet there is minimal return on...